BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Flower B, McCabe L, Le Ngoc C, Le Manh H, Le Thanh P, Dang Trong T, Vo Thi T, Vu Thi Kim H, Nguyen Tat T, Phan Thi Hong D, Nguyen Thi Chau A, Dinh Thi T, Tran Thi Tuyet N, Tarning J, Kingsley C, Kestelyn E, Pett SL, Thwaites G, Nguyen Van VC, Smith D, Barnes E, Ansari MA, Turner H, Rahman M, Walker AS, Day J, Cooke GS. High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. Open Forum Infect Dis 2021;8:ofab267. [PMID: 34337093 DOI: 10.1093/ofid/ofab267] [Reference Citation Analysis]
2 Hall EW, Schillie S, Vaughan AS, Jones J, Bradley H, Lopman B, Rosenberg ES, Sullivan PS. County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017. Hepatology 2021;74:582-90. [PMID: 33609308 DOI: 10.1002/hep.31756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Rammohan A. Current management & future directions in post-liver transplant recurrence of viral hepatitis. Journal of Liver Transplantation 2021;3:100027. [DOI: 10.1016/j.liver.2021.100027] [Reference Citation Analysis]
4 Madsen LW, Christensen PB, Øvrehus A, Bryde DMS, Holm DK, Lillevang ST, Nielsen C. Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C. Front Cell Infect Microbiol 2022;12:885824. [DOI: 10.3389/fcimb.2022.885824] [Reference Citation Analysis]
5 Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep. 2020;69:1-17. [PMID: 32271723 DOI: 10.15585/mmwr.rr6902a1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 44.5] [Reference Citation Analysis]
6 Madsen LW, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver Int 2021. [PMID: 34154034 DOI: 10.1111/liv.14991] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Prince HE, Marlowe EM, Schwab DS. Relationship between hepatitis C virus (HCV) IgG index values and quantitative HCV RNA results in HCV IgG-reactive serum samples. Diagn Microbiol Infect Dis 2021;100:115311. [PMID: 33524728 DOI: 10.1016/j.diagmicrobio.2021.115311] [Reference Citation Analysis]
8 Cooke GS, Pett S, McCabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch'Ng C, Stone B, Wiselka M, Forton D, McPherson S, Halford R, Nguyen D, Smith D, Ansari A, Dennis E, Hudson F, Barnes EJ, Walker AS. Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Res 2021;6:93. [PMID: 34405118 DOI: 10.12688/wellcomeopenres.16594.2] [Reference Citation Analysis]
9 Cooke GS, Pett S, Mccabe L, Jones C, Gilson R, Verma S, Ryder SD, Collier JD, Barclay ST, Ala A, Bhagani S, Nelson M, Ch’ng CL, Stone B, Wiselka M, Forton D, Mcpherson S, Halford R, Nguyen D, Smith D, Ansari MA, Ainscough H, Dennis E, Hudson F, Barnes EJ, Walker AS; the STOP-HCV trial team. Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy Mech Eval 2021;8:1-90. [DOI: 10.3310/eme08170] [Reference Citation Analysis]
10 Havens JR, Schaninger T, Fraser H, Lofwall M, Staton M, Young AM, Hoven A, Walsh SL, Vickerman P. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. BMJ Open 2021;11:e041490. [PMID: 34226208 DOI: 10.1136/bmjopen-2020-041490] [Reference Citation Analysis]